Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Kenneth J. Bloom, MD
Advertisement
Articles by Kenneth J. Bloom, MD
Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays
Advertisement
Latest Updated Articles
Dr. Bloom Compares HER2 Screening AssaysPublished: January 30th 2012 | Updated:
Dr. Bloom Explains Situations Requiring HER2 RetestingPublished: February 16th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5